Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Phase 1/2 Unknown 60 enrolled Adamis Pharmaceuticals Corporation

NaSingle-groupOpen-labelTreatment

Summary

This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.

Timeline

Start: 2011-08
Primary completion: 2016-08
Completion: 2017-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	APC-100	Small molecule	—	Oral

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Summary

Timeline

Drugs

Indications